Want to see CUPR full AI Analyst Report?
CUPR Stock Chart & Stats
$0.38
--
Market closed
$0.38
--
Day’s Range― - ―
52-Week Range$1.76 - $76.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.90M
Market Cap
$4.69M
Enterprise Value$15.53M
Total Cash (Recent Filing)$3.12M
Total Debt (Recent Filing)$482.72K
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding920,625
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap3.31
Enterprise Value/Revenue579.61
Enterprise Value/Gross Profit-941.13
Enterprise Value/Ebitda-5.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory MilestoneFDA 510(k) clearance for MEDIFLY (Lucilia cuprina) is a durable regulatory benchmark enabling U.S. commercial entry. It validates the technology, supports clinician adoption and reimbursement dialogues, and materially de-risks long-term commercial rollout in chronic wound care markets.
Dual-species Product PlatformControlling commercial rights to both maggot species creates a differentiated, adaptable product platform. That breadth supports tailored regional offerings, raises barriers to specialty competitors, and provides cross-selling and clinical flexibility that bolster medium-term market positioning.
Lower Leverage And Equity RecoveryRelatively low absolute debt reduces immediate refinancing pressure, and equity turning positive in 2025 signals improved solvency. Together these structural balance-sheet improvements increase financial flexibility to fund commercialization or clinical programs versus firms with heavier leverage.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow, with a sharp 2025 burn increase, creates ongoing dependence on external financing. That raises dilution and execution risk, constrains sustained investment in sales and manufacturing scale-up, and is a lasting funding overhang for the business.
Deteriorating ProfitabilityNegative gross profit and widening losses indicate weak unit economics or rising direct costs, undermining a path to sustainable margins. Without improving product-level economics, commercial expansion will be costly and profitability improvements will likely require structural changes or prolonged investment.
Governance And Capital Structure RiskThe capital overhaul concentrates voting power and expands authorized shares, increasing minority dilution and control entrenchment risk. That structural governance change can enable non-market-friendly future equity issuances and complicate investor protections over the medium term.
Cuprina Holdings (Cayman) Limited Class A News
CUPR FAQ
What was Cuprina Holdings (Cayman) Limited Class A’s price range in the past 12 months?
Cuprina Holdings (Cayman) Limited Class A lowest stock price was $1.76 and its highest was $76.00 in the past 12 months.
What is Cuprina Holdings (Cayman) Limited Class A’s market cap?
Cuprina Holdings (Cayman) Limited Class A’s market cap is $4.69M.
When is Cuprina Holdings (Cayman) Limited Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cuprina Holdings (Cayman) Limited Class A’s earnings last quarter?
Currently, no data Available
Is Cuprina Holdings (Cayman) Limited Class A overvalued?
According to Wall Street analysts Cuprina Holdings (Cayman) Limited Class A’s price is currently Overvalued.
Does Cuprina Holdings (Cayman) Limited Class A pay dividends?
Cuprina Holdings (Cayman) Limited Class A does not currently pay dividends.
What is Cuprina Holdings (Cayman) Limited Class A’s EPS estimate?
Cuprina Holdings (Cayman) Limited Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cuprina Holdings (Cayman) Limited Class A have?
Cuprina Holdings (Cayman) Limited Class A has 920,625 shares outstanding.
What happened to Cuprina Holdings (Cayman) Limited Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cuprina Holdings (Cayman) Limited Class A?
Currently, no hedge funds are holding shares in CUPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Technical Analysis
GeoVax Labs
―
HCW Biologics
―
Calidi Biotherapeutics
―
Psyence Biomedical
―
Aspire Biopharma Holdings
―
Ownership Overview
―
Insiders
0.17% Mutual Funds
― Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---